Table 3.
Adjusted associations between biomarkers and survival after recurrence (SAR) among patients by primary tumor site*$
| Proximal tumor | Distal tumor | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Biomarkers | Events/N | Adjusted median time in months (95% CI)1 | HR | 95% CI | P-value | Events/N | Adjusted median time in months (95% CI)1 | HR | 95% CI | P-value |
| MMR | ||||||||||
| dMMR | 41/55 | 30.3 (16.3-NR) | 0.57 | 0.40-0.83 | 0.0028 | 13/18 | 27.0 (24.4-NR) | 1.26 | 0.69-2.28 | 0.45 |
| pMMR | 308/393 | 19.0 (17.2-20.6) | Ref | 213/366 | 36.6 (33.3-43.3) | Ref | ||||
|
| ||||||||||
| KRAS | ||||||||||
| Codon 12 MT | 120/162 | 21.8 (19.7-25.3) | 0.85 | 0.65-1.12 | 0.26 | 81/113 | 27.0 (23.2-34.4) | 1.76 | 1.30-2.38 | 0.0003 |
| Codon 13 MT | 35/43 | 21.9 (16.6-30.2) | 0.91 | 0.61-1.36 | 0.65 | 20/25 | 33.8 (24.4-48.1) | 1.76 | 1.08-2.86 | 0.022 |
| WT | 194/243 | 16.7 (14.5-19.4) | Ref | 125/246 | 43.3 (37.1-55.1) | Ref | ||||
|
| ||||||||||
| BRAF | ||||||||||
| MT | 85/94 | 13.2 (9.9-16.7) | 1.90 | 1.37-2.64 | 0.0001 | 17/18 | 11.3 (6.5-23.4) | 5.84 | 3.27-10.43 | <.0001 |
| WT | 264/354 | 21.8 (19.3-23.8) | Ref | 209/366 | 39.2 (33.9-44.2) | Ref | ||||
|
| ||||||||||
| KRAS/BRAF | ||||||||||
| BRAF MT | 85/94 | 12.8 (9.9-16.0) | 1.90 | 1.37-2.64 | 0.0001 | 17/18 | 16.7 (6.6-25.5) | 5.84 | 3.27-10.43 | <.0001 |
| KRAS MT | 155/205 | 23.3 (21.1-27.2) | 0.87 | 0.67-1.12 | 0.28 | 101/138 | 29.1 (24.5-36.3) | 1.76 | 1.32-2.34 | <.0001 |
| Both WT | 109/149 | 19.1 (14.7-26.8) | Ref | 108/228 | 45.4 (38.5-61.4) | Ref | ||||
|
| ||||||||||
| MMR/BRAF | ||||||||||
| MT BRAF dMMR | 24/29 | 14.5 (11.8-NR) | 1.08 | 0.66-1.75 | 0.76 | 4/4 | 5.7 (2.8-NR) | 9.38 | 3.23-27.28 | <.0001 |
| WT BRAF dMMR | 17/26 | 30.3 (16.3-NR) | 0.59 | 0.35-0.99 | 0.047 | 9/14 | 27.0 (24.4-NR) | 1.13 | 0.56-2.29 | 0.73 |
| MT BRAF pMMR | 61/65 | 15.0 (9.9-16.7) | 1.92 | 1.35-2.73 | 0.0003 | 13/14 | 14.5 (6.6-NR) | 5.38 | 2.81-10.31 | <.0001 |
| WT BRAF pMMR | 247/328 | 20.7 (19.0-23.5) | Ref | 200/352 | 39.2 (34.4-44.2) | Ref | ||||
Abbreviations: HR, hazard ratio; CI, confidence interval; MT, mutant; WT, wild-type; NR, not reached
*
Adjusting for age, sex, performance score, T/N stage, tumor site, histologic grade, biomarkers (when applicable), and time-to-recurrence
$
Stratified Cox models with four arms as individual stratums.
1
Based on direct adjusted survival curves from Cox model